THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
Recruiting · NCT07446257 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Early phase 1 | 2026-09-03 | NCT07446257 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Maia Biotechnology | 3 |
| National Cancer Institute (NCI) | 3015 |
| University of Texas Southwestern Medical Center | 295 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Texas Southwestern Medical Center | Dallas | United States | 249 |